Omnix Medical is building a pipeline of first-in-class, leading edge anti-infective, all of which are designed to treat severe, potentially lethal infections associated with multi-drug resistances. Omnix Medical’s professional and clinical advisory teams are deploying vast and diverse experience to plan and execute all that is necessary to bring our pipeline to the market quickly and efficiently.

Omnix Medical’s pipeline maintains three major programs based on unique antimicrobial peptides in various stages of development.

The Company’s lead compound OMN6 targeting Gram-negative bacteria is currently being evaluated in a Phase-I trial in The Netherlands. OMN6 is being tested in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics in healthy subjects. OMN6 has been found safe, stable and highly effective on multidrug-resistant Acinetobacter baumannii (AB), especially Carbapenem-resistant AB (CRAB), the #1 priority pathogen according to the WHO/CDC. This compound is being developed as systemic IV treatment for patients suffering from severe or life-threatening infections. OMN6 has been designated Qualified Infectious Disease Product (QIDP) by the FDA for the following indications:

  • Hospital/Ventilator Associated Bacterial Pneumoniae (HABP/VABP)
  • Blood Stream Infections (BSI)
  • Complicated Urinary Tract Infections (cUTI)

OMN-Xf is a family of novel peptides in discovery stage at Omnix lab. OMNXf are being screened and developed as a therapy to treat infections caused by multidrug-resistant pathogenic Fungi. Where the arsenal of available therapies is limited.

OMN-GP is developed to treat infections caused by multidrug-resistant pathogenic Gram-positive bacteria, targeting pathogens like Methicillin-resistant Staphylococcus aureus (MRSA).